BMS-536924 is a dual IGF1R/IR kinase inhibitor that has been experimentally proven to inhibit acute myeloid leukemia (AML) proliferation and serve as a potential therapeutic target for AML [54]. This evidence concerns the gene IGF1R and acute myeloid leukemia.